Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109155 | 0.83 | DRD2 (0.33) | DRD2SIGMAR1CHRNA7DPP7POLB | |
| SCHEMBL20109229 | 0.83 | DRD2 (0.33) | DRD2SIGMAR1CHRNA7DPP7POLB | |
| SCHEMBL20113464 | 0.81 | ALDH1A1 (0.35) | HTT | |
| SCHEMBL20109240 | 0.74 | CHRNA7 (0.36) | DRD2SIGMAR1CHRNA7 | |
| SCHEMBL20109237 | 0.74 | MAPT (0.37) | DRD2SIGMAR1CHRNA7 | |
| SCHEMBL20109236 | 0.71 | CHRNA7 (0.33) | DRD2SIGMAR1CHRNA7 | |
| SCHEMBL20109233 | 0.71 | CHRNA7 (0.33) | DRD2SIGMAR1CHRNA7 | |
| SCHEMBL21866417 | 0.70 | CASP3 (0.37) | HTTMEN1KMT2A | |
| SCHEMBL20109352 | 0.70 | ALDH1A1 (0.36) | HTT | |
| SCHEMBL20109235 | 0.70 | SMN1; SMN2 (0.40) | CHRNA7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | DRD2 2561/4885SIGMAR1 2527/4885CHRNA7 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.